|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Use of programmed cell death protein ligand 1 assay to predict the outcomes of non-small cell lung cancer patients treated with immune checkpoint inhibitors显示文摘The recent discovery of immune checkpoints inhibitors, especially anti-programmed cell death protein 1(PD-1)and anti-programmed cell death protein ligand 1(PD-L1) monoclonal antibodies, has opened new scenarios in the management of non-small cell lung cancer(NSCLC) and this new class of drugs has achieved a rapid development in the treatment of this disease. However, considering the costs of these drugs and the fact that only a subset of patients experience long-term disease control, the identification of predictive biomarkers for the selection of candidates suitable for treatment has become a priority. The research focused mainly on the expression of the PD-L1 receptor on both tumor cells and/or immune infiltrates determined by immunohistochemistry(IHC). However, different checkpoint inhibitors were tested, different IHC assays were used, different targets were considered(tumor cells, immune infiltrates or both) and different expression thresholds were employed in clinical trials. In some trials the assay was used prospectively to select the patients, while in other trials it was evaluated retrospectively. Some confusion emerges, which makes it difficult to easily compare the literature data and to translate them in practice management. This mini-review shows the possibilities and pitfalls of the PD-L1 expression to predict the activity and efficacy of anti PD1/PD-L1 monoclonal antibodies in the treatment of NSCLC. | Carmelo Tibaldi Alice Lunghi Editta Baldini | 2017 | World Journal of Clinical Oncology2017，8，4： | 8 |
| 2 | Viral proteins and Src family kinases: Mechanisms of pathogenicity from a “liaison dangereuse”显示文摘To complete their life cycle and spread, viruses interfere with and gain control of diverse cellular processes, this most often occurring through interaction between viral proteins(VPs) and resident protein partners. Among the latter, Src family kinases(SFKs), a class of non-receptor tyrosine kinases that contributes to the conversion of extracellular signals into intracellular signaling cascades and is involved in virtually all cellular processes, have recently emerged as critical mediators between the cell's infrastructure and the viral demands. In this scenario, structural or ex novo synthesized VPs are able to bind to the different domains of these enzymes through specific short linear motifs present along their sequences. Proline-rich motifs displaying the conserved minimal consensus PxxP and recognizing the SFK Src homology(SH)3 domain constitute a cardinal signature for the formation of multiprotein complexes and this interaction may promote phosphorylation of VPs by SFKs, thus creating phosphotyrosine motifs that become a docking site for the SH2 domains of SFKs or other SH2 domain-bearing signaling molecules. Importantly, the formation of these assemblies also results in a change in the activity and/or location of SFKs, and these events are critical in perturbing key signalingpathways so that viruses can utilize the cell's machinery to their own benefit. In the light of these observations, although VPs as such, especially those with enzyme activity, are still regarded as valuable targets for therapeutic strategies, multiprotein complexes composed of viral and host cell proteins are increasingly becoming objects of investigation with a view to deeply characterize the structural aspects that favor their formation and to develop new compounds able to contrast viral diseases in an alternative manner. | Mario Angelo Pagano Elena Tibaldi Giorgio Palù Anna Maria Brunati | 2013 | World Journal of Virology2013，2，2： | 3 |
| 3 | Practical guidance on intensification of insulin therapy with BIAsp 30:a consensus statement显示文摘 | Unnikrishnan AG Tibaldi J Hadley-Brown M | | 0，，11： | 2 |
| 4 | Closure of fistula‐in‐ano with laser – FiLaC?: an effective novel sphincter‐saving procedure for complex disease显示文摘 | P. Giamundo M. Geraci L. Tibaldi M. Valente | 2014 | Colorectal Dis2014，，2： | 2 |
| 5 | Crucial role of HsPg0 in the Akt-dependent promotion of angiogenic-like effect of glucose-regulated protein94 ( Grp94 ) -IgG complexes显示文摘 | Tramentozzi E Tibaldi E Brunati AM | 2011 | J Cell Mol Meal2011，15，12： | 1 |
| 6 | New blocking antibodies impede adhesion,migrationand survival of ovarian cancer cells,highlighting MFGE8 as a potential therapeutic target of human Ovarian Carcinoma显示文摘 | Tibaldi L Leyman S Nicolas A | 2013 | PloS One2013，8，72： | 1 |
| 7 | Pharmacogenetic study of patients with advanced non-small cell lung cancer(NSCLC)treated with second-line pemetrexed or pemetrexed-carboplatin显示文摘 | Tiseo M Giovannetti E Tibaldi C | 2012 | Lung Cancer2012，78，1： | 1 |
| 8 | On the operational predictability of blocking显示文摘 | Tibaldi S F Moheni | 1990 | Tellus1990，42，： | 1 |
| 9 | Evolution of insulin: from human to analog 显示文摘 | Tibaldi J M | 2014 | Am J Med2014，127，10： | 1 |
| 10 | Mechanisms of resistance to crizotinib in pa- tients with ALK gene rearranged non-small-cell lung can- cer显示文摘 | Tibaldi C | 2014 | Pharmacogenomics2014，15，2： | 1 |
| 11 | Cisplatin-vindesine-mitomyvin (MVP) Vs cisplatin-ifosfamide-vinorelbine (PIN) Vs carboplatin vinoprelbine (CaN) in patients with advanced nonsmall cell lung cancer: a FONICAP randomized phase study显示文摘 | Tibaldi C Ardizzoni A | 1998 | Br J Cancer1998，77，12： | 1 |
| 12 | Dietary threonine requirement of juvenile European sea bass (Dicentrarchus labrax) 显示文摘 | Tibaldi E Tulli F | 1999 | Aquac1999，177，： | 1 |
| 13 | Increased dose-intensity of gemcitabine in advanced non small cell lung cancer(NSCLC):a muhicenter phase II study in elderly patients from the'polmone to- scano group'(POLTO)显示文摘 | Tibaldi C Ricci S Russo F | 2005 | Lung Cancer2005，48，1： | 1 |
| 14 | The utility of theNecessity-Concems Framework in explaining treatment non-adherence in four chronic illness groups in Italy显示文摘 | Tibaldi G Clatworthy J Torchio E | 2009 | ChronicIlln2009，5，2： | 1 |
| 15 | Roles of the mean meridional circulation in atmospheric budgets of angular momentum and sensible heat 显示文摘 | Wu Guoxiong Tibaldi S | 1988 | Chinese Journal of Atmospheric Sciences1988，12，1： | 1 |
| 16 | Biphasic Insulin Aspart in Type 2 Diabetes Mellitus:Evaluation显示文摘 | Gough SCL Tibaldi J | 2007 | Clin Drug Invest2007，27，5： | 1 |
| 17 | Impact of cytidine deaminase polymorphisms on toxicity after gemcitabine:The question is still ongoing显示文摘 | Giovannetti E Tibaldi C Falcone A | 2010 | J Clin Oncol2010，28，14： | 1 |
| 18 | Inherited germline T790M mutation and somatic epidermal growth factor re- ceptor mutations in non-small cell lung cancer patients显示文摘 | Tibaldi C Giovannetti E Vasile E | 2011 | J Thorac Oncol2011，6，2： | 1 |
| 19 | Cervicovaginal infections during pregnancy:epidemiological and microbiological aspects显示文摘 | Benedetto C Tibaldi C Marozio L | 2004 | J Matern Fetal Neonatal Med2004，16，2： | 1 |
| 20 | Erlotinib after Failure of Gefitinib in Patients with Advanced Non-small Cell Lung Cancer Previously Responding to Gefitinib显示文摘 | Enrico Vasile Carmelo Tibaldi Antonio Chella Alfredo Falcone | 2008 | Journal of Thoracic Oncology2008，，8： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员